Evaluation of Adalimumab Biosimilar (Exemptia: ZRC 3197) in treatment of Psoriatic Arthritis with concomitant moderate to severe chronic plaque psoriasis- An open labelled prospective pilot case series

Published: 21 December 2019| Version 1 | DOI: 10.17632/7bk9p3624z.1
Contributors:
Sujay Khandpur, Prateek Sondhi, neha taneja, Preeti Sharma, Dayasagar Das, Alpana Sharma, V Sreenivas

Description

Supplemental Figure 1. Change in median PASI score with time on adalimumab biosimilar (Exemptia) Supplemental Figure 2: Change in median DAPSA, IGA and PGA score (for skin and joint disease) with time on adalimumab biosimilar (Exemptia)

Files

Institutions

  • All India Institute of Medical Sciences

Categories

Biologicals, Psoriasis

Licence